Prospective Real-Life Multicenter Study of Tildrakizumab 200 mg for Moderate-to-Severe Psoriasis: Who Is the Ideal Patient?. Dermatology Practical & Conceptual, [S. l.], v. 14, n. 4, p. e2024284, 2024. DOI: 10.5826/dpc.1404a284. Disponível em: https://dpcj.org/index.php/dpc/article/view/4769.. Acesso em: 6 dec. 2024.